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An epidemic of drug overdose deaths has led to calls for programs and policies to limit misuse and diversion of opioid medications. Any parallel call to consider the risk of iatrogenic addiction when treating pain has been muted in comparison.
We have moved beyond questions of nonmedical use, abuse, and diversion to highlight the role of prescription opioids in causing addiction even when prescribed and used appropriately.
Unfortunately, current evidence is insufficient, and a rapid expansion of longitudinal research is urgently needed to guide clinicians in balancing the need for opioids with the risk of adverse consequences. Meanwhile, medical education should place greater emphasis on the abuse liability of prescription opioids, and providers should endeavor to attenuate risk when possible. ( THE UNITED STATES CONtinues to suffer from a startlingly severe epidemic of drug overdose deaths, 1---6 with approximately 46 Americans dying per day in 2010 from an overdose involving prescription opioids. 7 The increase in overdose deaths was directly paralleled by dramatic increases in the sale of opioid pharmaceuticals between 1999 and 2010. 7---13 Attention to this health threat has grown exponentially in recent years, but discussion and interventions have focused almost exclusively on issues such as illegitimate prescribing, nonmedical use, diversion, and overdose.
3---5,7,8,10,11,13---30 These topics are important but pertain primarily to individuals who already engage in nonmedical use of opioids. A different question is why nonmedical opioid use occurred in the first place. It is universally understood that some small proportion of individuals will intentionally misuse opioid medications for their euphoric effects, and many assume the initial decision to begin doing so is entirely volitional. Largely unaddressed is that some individuals transition to nonmedical use and addiction despite their intention to use medications only as directed and only for pain relief. To date, few articles have alluded to iatrogenic addiction in the context of the current opioid epidemic. 5, 22, 23, 31 None have explicitly called for a disambiguated determination of the role of inadvertent iatrogenic addiction as opposed to the role of intentional misuse and diversion.
We have moved beyond widespread recognition that prescription opioids have contributed to increased fatalities and beyond interventions that bluntly restrict the supply of prescription opioids to prevent misuse and diversion. Instead, we specifically focus on the issue of iatrogenic addiction, the degree to which it is underrecognized, and the need to (1) fully characterize its contribution to the current health crisis, (2) identify patients at risk and intervene early to prevent new cases of opioid use disorders, and (3) consider the issues of acute pain treatment and unscheduled care settings in addition to the more commonly discussed issue of chronic pain management. Most importantly, we seek to remind medical providers that wellintentioned efforts to treat pain may inadvertently lead to opioid use disorders, even if patients follow medical direction precisely. We also suggest urgent steps, including a call to arms for rapid expansion in research activity and better integration of existing evidence into provider education and clinical practice. 
OPIOID PRESCRIBING AND OVERDOSE DEATHS

ORIGIN OF CURRENT PRACTICE IN PAIN TREATMENT
Factors contributing to increases in opioid prescribing have been detailed elsewhere. 5, 12, 22, 25, 29, 36 The more permissive attitude toward opioids for pain treatment began in the 1980s, after several reports suggested a low potential for iatrogenic addiction in patients treated with opioids. 33 The general lack of consistent and reliable information has allowed competing viewpoints, both for and against the assertion that iatrogenic addiction is a frequent consequence of opioid therapy. Knowledge gaps are even more pronounced with respect to acute pain and unscheduled care settings.
Evidence to Date
Studies from the 1980s reported addiction rates after opioid treatment as low as 0.03% to 0.1% in hospitalized patients with no prior addiction history and 5% for patients with chronic noncancer pain. 37, 38, 52, 53 In the early to mid-1990s, studies began to report addiction among patients treated with opioids for acute or subacute pain ranging from 3.8% to 27%, although these studies did not include a definition of addiction and did not specify whether addiction was iatrogenic in etiology. 47 More recent studies have suggested higher rates of opioid misuse, ranging from 3.27% to 56%, depending on specific definitions and outcome measures. 16 A few studies have addressed the risk of iatrogenic addiction somewhat more directly. Opioidnaïve patients receiving an opioid prescription within seven days of short-stay surgery were 44% more likely to become long-term opioid users within one year than were those not receiving opioids, 17 and prolonged use of opioids has been associated with self-reported patient concern regarding addiction. 18 Another study found that 44% of patients in a methadone maintenance program, who also had chronic pain, reported that opioids prescribed medically for their pain had led to an addiction. 19 
Arguments Against Iatrogenic Addiction
Support in favor of prescription opioid safety is intuitively predicated on the belief that opioids carry a low risk of addiction when prescribed and used appropriately. This assertion is not entirely without merit. Pain is a significant health problem, 43 
Arguments for Iatrogenic Addiction
Despite the validity of such arguments, even pain management advocates, who led the initial charge in favor of more aggressive use of opioids, now recognize the imprudence of minimizing the addiction potential of pharmaceutical opioids. 67 First, it is difficult to believe that the parallel rise in prescriptions and associated harms is mere correlation without causation, particularly because of the inherent abuse liability of opioids. ; and 5. overdose prevention education and naloxone distribution to prevent overdose fatalities.
22,75---78
These interventions, although important, have been discussed elsewhere and do not directly address the problem of how iatrogenic addiction is initiated. However, simply reducing the supply of prescribed opioids available to those affected by substance use disorders, in the absence of diagnosis and treatment, can have unintended consequences, such as switching to heroin as a less expensive or more easily available alternative.
29,79
Various other measures may have some inadvertent effect on the problem of iatrogenic addiction simply by curtailing the degree to which pain is treated (i.e., opioid amount, duration, potency, and frequency of use) and thus the extent of exposure.
Recently, emergency physicians have been encouraged to limit the amount and duration of opioid medication provided by any single prescription, avoid replacing lost or stolen prescriptions, and avoid treating chronic pain or refilling opioid prescriptions. 51 and one has explicitly indicated that screening for factors that predispose individuals to substance use disorders could help prevent iatrogenic addiction.
23
RECOMMENDATIONS FOR FUTURE ACTION
Any attempt to develop recommendations to address the issue of iatrogenic addiction in clinical practice is challenged by considerable deficiencies in the available evidence base. Hence, our primary recommendation is to expand the volume of research on iatrogenic addiction with great urgency, and research methods should be sufficiently rigorous to inform clinical practice guidelines. In addition, we need to vastly improve collaborative work across the fields of addiction and medicine to ensure that empirical evidence is transdisciplinary and translated into clinical practice and health policy.
Research
Advances in addiction science have improved our knowledge of opioid abuse liability and risk factors associated with opioid misuse and addiction, but the risk of addiction from appropriate medical use remains poorly defined. Evidence that does exist often does not transfer between siloed disciplines; what may seem obvious in the field of addiction may not be common knowledge to the professionals prescribing opioid medications for pain relief. In our clinical experience, few physicians outside chronic pain management are familiar with the term "iatrogenic addiction," even though both words in that term are in common use separately.
The most fundamental need is for more precise determination of how frequently and under what circumstances iatrogenic addiction occurs. There is knowledge about the individual-, family-, and environment-level factors, including nonmedical use of prescription opioids, which are associated with the development of illicit drug use and addiction.
58---63,86---92 However, there is little understanding of how these and yet other unidentified factors specifically relate to iatrogenic opioid addiction.
There is even less understanding of risk factors at the health care system level and how external factors, such as health care setting, prescriber specialty, type of pain, and prescribing patterns are associated with iatrogenic addiction. Characterizing the range of contributory factors would provide a foundation for further research and allow interventions to be targeted proportionally to areas of greatest need. It would also suggest which actions should be avoided to reduce the incidence of iatrogenic addiction. Perhaps the most important intervention would be the application of tools to appropriately riskstratify patients before prescribing opioids to manage pain. Presently, there is no available method with adequate sensitivity or specificity to do so, and inaccurate assessments promise unnecessary stigma and inappropriate exclusion from opioid therapy. 12 After it becomes possible to accurately estimate the risk of iatrogenic addiction, there will be a need for research to guide clinicians on how to balance the risk of iatrogenic addiction with the risk of undertreated pain. Currently, there is no clear understanding of how patients or providers should balance these risks, either for individuals with an elevated risk of iatrogenic addiction or for those already suffering from the condition. For example, in cases of elevated risk, we do not know when it is appropriate to forgo opioids, use alternate dosing or abuse-deterrent formulations, or treat as needed but monitor closely. If close monitoring is adopted, we do not know how frequently this should occur, what targets should be selected (e.g., level of euphoria with appropriate use? indications of misuse?), or how best to measure these targets. When iatrogenic addiction has occurred, the best strategies for early recognition and intervention are neither characterized nor empirically tested. In particular, we do not know if, and to what extent, individuals with iatrogenic addiction might require different treatment strategies than are used for other forms of opioid addiction.
Ultimately, newly developed interventions need to be translated into practice. This will be facilitated if evidence is of high quality and developed within the settings and conditions for which the intervention is intended. It will also be vital to incorporate implementation science and effectiveness-implementation hybrid research designs to expedite the translation of empirical findings into clinical practice and public health policies. 93 Such research is inherently multidisciplinary and should include the perspectives of experts in addiction, pain, policy, public health, and ethics as well as health economists, law enforcement officials, advocacy groups, patients, and medical providers.
Education
The full range of available evidence on iatrogenic addiction has not been integrated into medical education to the same degree as has the more selected evidence initially promoted by pain advocates. We suggest several key points of desirable content.
Most fundamentally, providers need to understand the complex etiology and natural progression of opioid addiction and be reminded that appropriate medical use of prescription opioids can, in some unknown proportion of cases, initiate a progression toward misuse and ultimately addiction. The need to learn which patient characteristics are associated with developing addiction directly follows that foundation, as does the need to screen for those factors before prescribing opioid medications. 58---62,86---92 This should be differentiated from the important but different task of screening for opioid use disorders that are already present. Providers will also need to adopt appropriate strategies for determining when and how opioids should be prescribed. This involves determining not only the risk of iatrogenic addition but also the degree to which opioids are appropriate and necessary. How opioids may be insufficient to treat or may even exacerbate pain 94---97 and may reduce functional status 24 should be understood along with more commonly recognized side effects and benefits. It is interesting that the majority of individuals with chronic pain report not using opioids, and those who do report use of opioids still indicate high levels of chronic pain. 96 Providers should also have more training in alternative approaches to managing pain, particularly in high-risk populations.
These include nonopioid pain medications, mixed narcotic agonist---antagonists such as buprenorphine, and physical and occupational therapy.
22,98
Practice Adding nuance to current practice in pain treatment will be a delicate matter. The push to incorporate addiction risk into medical decision-making should not come at the expense of improvements in pain management. Nonetheless, it may be appropriate to forgo opioids in situations where, on the basis of the best available evidence, the risks of iatrogenic addiction may outweigh the consequences of undertreated pain. When in doubt, shared decision-making approaches may be desirable and, in the setting of chronic pain, could combine the clinical expertise of pain specialists and addiction treatment providers. In addition, alternative pain management strategies should be covered by health insurance so that providers can be reimbursed appropriately for providing these services.
When opioids are prescribed in situations of greater than usual risk, a variety of measures may be necessary. These might include alternate prescribing patterns (e.g., adjusted dosage, potency, duration), patient education on the risks of iatrogenic addiction, and serial evaluation to identify opioid use disorders at the earliest possible stage. Other adjuncts might include more generalized use of pain management contracts, which are currently used only in the context of chronic pain. In the case of patients who have already been diagnosed with a substance use disorder, medication-assisted treatment may be considered in addition to nonopioid pain management.
Even when the risk of iatrogenic addiction is not elevated, providers should still be encouraged to advise patients of the risks of iatrogenic addiction and any recommendations to mitigate that risk. Providers commonly warn patients about the danger of sedation when prescribing opioids; warning about the risks of overdose and addiction should be as, if not more, important.
CONCLUSIONS
Pain relief is a core component of routine medical practice, but trends in morbidity and mortality associated with prescription opioids are alarming. Even if iatrogenic addiction occurs in only a small proportion of cases, the health consequences would still be considerable because of the absolute number of patients prescribed opioids annually. Physicians should once again become mindful that prescription opioids may lead to addiction in susceptible patients, even when prescribed and used appropriately. This recognition necessarily requires that the mission to treat pain must be balanced to at least some degree by a mission to prevent opioid abuse and addiction. Unfortunately, methods to achieve this balance are largely unknown. A true call to arms, broadly heralded across many research communities, is urgently needed to guide our response to this health emergency. 
